- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Remus Pharmaceuticals released its share capital audit report, confirming all shares are held in dematerialized form. The report highlighted a key capital event: the company's board approved a 1:1 bonus share issue. This means shareholders received one new fully paid-up share of Rs. 10 for every existing share. A total of 58.92 lakh new shares, valued at Rs. 5.892 Cr, were issued. This bonus issue, after receiving shareholder approval, has been allotted, listed, and is now trading, effectively doubling the company's listed equity capital to 1.1784 Cr shares. This move typically enhances liquidity and benefits shareholders.